Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial.

Carmen de la RochaMarco A Cid-LópezBlanca I Venegas-LópezSandra C Gómez-MéndezAdriana Sánchez-OrtizAlma M Pérez-RíosRicardo A Llamas-VelázquezAidé I Meza-AcuñaBárbara Vargas-ÍñiguezDaniela Rosales-GalvánAlejandra Tavares-VáldezNizdali Luna-GudiñoCinthia V Hernández-PuenteJovana MilenkovicCecilia Iglesias-PalomaresMiriam Méndez-Del VillarGerardo A Gutiérrez-DieckCarlos G Valderrábano-RoldánJennefer Mercado-CerdaJocelyn G Robles-BojórquezArieh Roldán Mercado-Sesma

Published in: BMC infectious diseases (2022)

At standard doses, ivermectin is not effective to prevent progression to a severe state or reducing symptoms in adults with asymptomatic and mild COVID-19. Trial registration The study was registered with ClinicalTrial.gov (NCT04407507) on May 29, 2020.

Keyphrases

coronavirus disease
sars cov
phase iii
clinical trial
study protocol
respiratory syndrome coronavirus
early onset
drug administration
phase ii
double blind
depressive symptoms